{"id":"NCT00819091","sponsor":"Boehringer Ingelheim","briefTitle":"Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug","officialTitle":"A Randomized, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 1356 (5 mg Administered Orally Once Daily) Over 18 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control (HbA1c 7.0-10%) Despite Background Therapy With a Sulfonylurea Drug.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-12","primaryCompletion":"2010-01","completion":null,"firstPosted":"2009-01-08","resultsPosted":"2011-08-01","lastUpdate":"2014-06-27"},"enrollment":245,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"BI 1356","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"BI 1356","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Efficacy and safety of BI 1356 compared to placebo in patients with type 2 diabetes who have insufficient glycaemic control despite treatment with a sulfonylurea drug.","primaryOutcome":{"measure":"Change From Baseline in HbA1c (Glycosylated Hemoglobin) at Week 18","timeFrame":"Baseline, week 18","effectByArm":[{"arm":"Placebo","deltaMin":-0.07,"sd":0.1},{"arm":"Linagliptin 5.0 mg","deltaMin":-0.54,"sd":0.07}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":45,"countries":["United States","Argentina","Hungary","India","Japan","Poland","Russia"]},"refs":{"pmids":["24169807","22939034","22234149"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":84},"commonTop":["Hyperglycaemia"]}}